These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1591061)

  • 21. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.
    McDermott DF; Mier JW; Lawrence DP; van den Brink MR; Clancy MA; Rubin KM; Atkins MB
    Clin Cancer Res; 2000 Jun; 6(6):2201-8. PubMed ID: 10873069
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alteration of dacarbazine pharmacokinetics after interleukin-2 administration in melanoma patients.
    Chabot GG; Flaherty LE; Valdivieso M; Baker LH
    Cancer Chemother Pharmacol; 1990; 27(2):157-60. PubMed ID: 2249333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
    Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment of metastatic melanoma with dacarbazine recombinant interferon alfa 2A combination: results of multicentric study].
    Avril MF; Beerblock K; Dreno B; Delaunay M; Bonerandi JJ; Guillaume JC; Souteyrand P; Kalis B; Chevrant-Breton J; Verret J
    Bull Cancer; 1990; 77(12):1183-91. PubMed ID: 2081278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II study of dacarbazine, cisplatin, interferon-alpha and high-dose interleukin-2 in 'poor-risk' metastatic melanoma.
    Proebstle TM; Scheibenbogen C; Sterry W; Keilholz U
    Eur J Cancer; 1996 Aug; 32A(9):1530-3. PubMed ID: 8911113
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant interleukin-2 (rIL-2) given intrasplenically and intravenously for advanced malignant melanoma. A phase I and II study.
    Thatcher N; Dazzi H; Johnson RJ; Russell S; Ghosh AK; Moore M; Chadwick G; Craig RD
    Br J Cancer; 1989 Nov; 60(5):770-4. PubMed ID: 2803954
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma.
    Gaynor ER; Weiss GR; Margolin KA; Aronson FR; Sznol M; Demchak P; Grima KM; Fisher RI; Boldt DH; Doroshow JH
    J Natl Cancer Inst; 1990 Sep; 82(17):1397-402. PubMed ID: 2388289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sequential treatment of melanoma patients who progressed on interleukin-2 and dacarbazine by alpha-interferon and dacarbazine--a preliminary report.
    Merimsky O; Inbar M; Shiloni E; Ron I; Chaitchik S
    Mol Biother; 1990 Dec; 2(4):208-10. PubMed ID: 2288720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biochemotherapy with thymosin alpha 1, interleukin-2 and dacarbazine in patients with metastatic melanoma: clinical and immunological effects.
    Lopez M; Carpano S; Cavaliere R; Di Lauro L; Ameglio F; Vitelli G; Frasca AM; Vici P; Pignatti F; Rosselli M
    Ann Oncol; 1994 Oct; 5(8):741-6. PubMed ID: 7826907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemo-immunotherapy in patients with metastatic melanoma using sequential treatment with dacarbazine and recombinant human interleukin-2: evaluation of hematologic and immunologic parameters and correlation with clinical response.
    Isacson R; Kedar E; Barak V; Gazit Z; Yurim O; Kalichman I; Ben-Bassat H; Biran S; Schlesinger M; Franks CR
    Immunol Lett; 1992 Jul; 33(2):127-34. PubMed ID: 1446917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin-2 in combination with interferon-alpha in disseminated malignant melanoma and advanced renal cell carcinoma. A phase I/II study.
    Bergmann L; Weidmann E; Mitrou PS; Runne U; Keilholz U; Bartsch HH; Franks CR
    Onkologie; 1990 Apr; 13(2):137-40. PubMed ID: 2197585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase-II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanoma.
    Lindemann A; Höffken K; Schmidt RE; Diehl V; Kloke O; Gamm H; Hayungs J; Oster W; Böhm M; Kolitz JE
    Cancer Immunol Immunother; 1989; 28(4):275-81. PubMed ID: 2784715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interleukin-2 therapy for refractory and relapsing lymphomas.
    Tourani JM; Levy V; Briere J; Levy R; Franks C; Andrieu JM
    Eur J Cancer; 1991; 27(12):1676-80. PubMed ID: 1782082
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin-2 in association with increasing doses of interferon-gamma in patients with advanced cancer.
    Viens P; Blaise D; Stoppa AM; Brandely M; Baume D; Olive D; Resbeut M; Delpero JR; Lopez M; Aubert C
    J Immunother (1991); 1992 Apr; 11(3):218-24. PubMed ID: 1515426
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma.
    Thompson JA; Gold PJ; Markowitz DR; Byrd DR; Lindgren CG; Fefer A
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S29-34. PubMed ID: 9457390
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IL-2 phase II trial in metastatic melanoma: analysis of clinical and immunological parameters.
    Dorval T; Mathiot C; Chosidow O; Revuz J; Avril MF; Guillaume JC; Tursz T; Brandely M; Pouillart P; Fridman WH
    Biotechnol Ther; 1992; 3(1-2):63-79. PubMed ID: 1305893
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.
    Keilholz U; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; Thomas J; Proebstle TM; Schmittel A; Schadendorf D; Velu T; Negrier S; Kleeberg U; Lehman F; Suciu S; Eggermont AM
    J Clin Oncol; 2005 Sep; 23(27):6747-55. PubMed ID: 16170182
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Case report: development of Hodgkin's disease in patient receiving long-term administration of dacarbazine and interleukin-2 for metastatic melanoma.
    Flaherty LE; Schwert R; Redman BG
    J Natl Cancer Inst; 1990 Aug; 82(16):1360. PubMed ID: 2380992
    [No Abstract]   [Full Text] [Related]  

  • 39. A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma.
    Chang J; Atkinson H; A'Hern R; Lorentzos A; Gore ME
    Eur J Cancer; 1994; 30A(14):2093-5. PubMed ID: 7857710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells.
    Bar MH; Sznol M; Atkins MB; Ciobanu N; Micetich KC; Boldt DH; Margolin KA; Aronson FR; Rayner AA; Hawkins MJ
    J Clin Oncol; 1990 Jul; 8(7):1138-47. PubMed ID: 2358835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.